| Título : |
Anti-VEGF therapy in pituitary carcinoma |
| Tipo de documento : |
documento electrónico |
| Autores : |
Luis Vicente Syro Moreno, |
| Fecha de publicación : |
2011 |
| Títulos uniformes : |
Pituitary
|
| Idioma : |
Inglés (eng) |
| Palabras clave : |
Pituitary carcinoma angiogenesis inhibitors vascular endothelial growth factor-A bevacizumab temozolomide |
| Resumen : |
We report the case of a 44-year-old male patient with an aggressive silent corticotroph cell pituitary adenoma, subtype 2. In that it progressed to carcinoma despite temozolomide administration, anti-VEGF therapy was begun. MRI, PET scan and pathologic analysis were undertaken. After 10 months of anti-VEGF (bevacizumab) treatment no progression of the lesion was noted. The tumor was biopsied and morphological analysis showed severe cell injury, vascular abnormalities and fibrosis. Bevacizumab treatment has continued for additional 16 months to present with stabilization of disease as documented on serial MRI and PET scans. This is the first case of a bevacizumab-treated pituitary carcinoma with long-term, now 26 months, control of disease. The present findings are promising in that anti-angiogenic therapy appears to represent a new option in the treatment of aggressive pituitary tumors. |
| Mención de responsabilidad : |
Leon D Ortiz, Luis V Syro, Bernd W Scheithauer, Ayca Ersen, Humberto Uribe, Camilo E Fadul, Fabio Rotondo, Eva Horvath, Kalman Kovacs |
| Referencia : |
Pituitary. 2012 Sep;15(3):445-9. |
| DOI (Digital Object Identifier) : |
10.1007/s11102-011-0346-8 |
| PMID : |
21918831 |
| En línea : |
https://link.springer.com/article/10.1007%2Fs11102-011-0346-8 |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3568 |
Anti-VEGF therapy in pituitary carcinoma [documento electrónico] / Luis Vicente Syro Moreno, . - 2011. Obra : PituitaryIdioma : Inglés ( eng) | Palabras clave : |
Pituitary carcinoma angiogenesis inhibitors vascular endothelial growth factor-A bevacizumab temozolomide |
| Resumen : |
We report the case of a 44-year-old male patient with an aggressive silent corticotroph cell pituitary adenoma, subtype 2. In that it progressed to carcinoma despite temozolomide administration, anti-VEGF therapy was begun. MRI, PET scan and pathologic analysis were undertaken. After 10 months of anti-VEGF (bevacizumab) treatment no progression of the lesion was noted. The tumor was biopsied and morphological analysis showed severe cell injury, vascular abnormalities and fibrosis. Bevacizumab treatment has continued for additional 16 months to present with stabilization of disease as documented on serial MRI and PET scans. This is the first case of a bevacizumab-treated pituitary carcinoma with long-term, now 26 months, control of disease. The present findings are promising in that anti-angiogenic therapy appears to represent a new option in the treatment of aggressive pituitary tumors. |
| Mención de responsabilidad : |
Leon D Ortiz, Luis V Syro, Bernd W Scheithauer, Ayca Ersen, Humberto Uribe, Camilo E Fadul, Fabio Rotondo, Eva Horvath, Kalman Kovacs |
| Referencia : |
Pituitary. 2012 Sep;15(3):445-9. |
| DOI (Digital Object Identifier) : |
10.1007/s11102-011-0346-8 |
| PMID : |
21918831 |
| En línea : |
https://link.springer.com/article/10.1007%2Fs11102-011-0346-8 |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3568 |
|  |
Inicio
Anti-VEGF therapy in pituitary carcinoma
